| Position | Action |
|---|---|
| No confirmed close above $410.64 (50 SMA) on >7M volume with bullish MACD cross by mid-September | Reduce exposure 15-25% before October binary print |
| Close below $380 on >7M volume | Trim 25-50% to Underweight |
| Close below $344 (200 SMA) on any volume | Exit fully to Sell |
| Rally into $430-$450 zone | Trim concentration ahead of October risk |
| Measured add at $395 with price retest and bullish MACD divergence | Deploy incremental capital near $380 hard stop |
UNH's recent pullback from $436 to $407.55 is a healthy mid-cycle consolidation creating a buyable entry point, with ~14.7% upside to $475.23 fair value supported by $22.8B in TTM free cash flow, institutional accumulation, and scale advantages that benefit from 2027 MA industry consolidation.
| Indicator | Value | Signal |
|---|---|---|
| MACD | 0.82 | bearish |
| MACD Signal | 3.78 | bearish |
| MACD Histogram | -2.97 | bearish |
| RSI(14) | 43.09 | neutral |
| 10 EMA | 418.28 | bearish |
| 50 SMA | 410.64 | neutral |
| 200 SMA | 342.06 | bullish |
| Bollinger Middle (20 SMA) | 423.17 | neutral |
| Bollinger Upper Band | 436.57 | neutral |
| Bollinger Lower Band | 409.78 | bullish |
| ATR(14) | 11.55 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Maintain UNH with mandatory hedging and pre-committed triggers; do not add above $415 or trim below $390 absent breakdown
Hold with $450 target (~10% upside) reflects the genuinely two-sided setup where neither the bull's $475 nor the bear's $344 is the central case. The mechanical difference from prior HOLD is explicit: mandatory hedge replaces passive holding, pre-committed triggers replace discretionary judgment, and time-boxed reduction converts passive Hold into active risk management. Do not add above $415 absent breakout; do not trim below $390 absent breakdown; the mandatory put spread neutralizes the binary catalyst that previously destroyed alpha.
When: Close below $380 on >7M volume
Then: Trim 25-50% to Underweight
Janus Henderson Forty Fund and Vulcan Value Partners are independently accumulating UNH based on fundamental conviction, not momentum chasing.
· concedes: Stock closed below the 50 SMA for the first time in the uptrend; MACD at 0.82 is threatening to cross zero; RSI is at 43 and falling; Near-term momentum is technically weak
UNH shows a textbook topping pattern with a key reversal day at the highs on 13M volume, MACD threatening zero-line crossover, RSI falling from 86 to 43, and management having paused buybacks near the highs—suggesting the stock is in the early stages of a multi-month correction that targets $400, then $380, then the 200 SMA at $344.
· concedes: Technical bounce from lower Bollinger Band is possible in the $10-15 range; Q1 2026 FCF of $8.15B was a clean quarter; Tactical re-entry possible if MACD crosses back above zero with close above 50 SMA on >7M volume
→ vs conservative: Conservative analyst misreads Bollinger Band mechanics - close 2.32 points below lower band at $409.78 signals mean reversion due, not trend continuation; fighting the indicator instead of reading it
→ vs conservative: Conservative MACD argument is weak - at 0.82 at zero line, every major MACD reset has been a launching pad historically; using same data but reading it backward
→ vs conservative: Conservative stop at $380 and technical avoidance means missing the re-rating already 70% complete and conceding another 15-20% upside from multiple expansion
→ vs conservative: The 2027 Part D and MA redraw risks are known knowns already priced into the tape; base case management guidance validates MA repricing actions
→ vs neutral: Neutral 'balanced two-sided setup' framing is wrong - asymmetry is 2.5 to 1 reward-to-risk ratio; waiting for confirmation above 50 SMA means buying at $415-420, eliminating entire edge
→ vs neutral: October Q3 earnings wait is performance destruction - smart money already positioned; anyone waiting misses July-to-October rally that early holders capture
→ vs neutral: Put spread hedge proposal ($400/$365) costs real premium bleeding the entire way up while capping gains; 'tax on being wrong about being right'
| neutral |
| Price vs 200 SMA | above by ~19% | bullish |
Support: 406.8 · 400 · 342.06 | Resistance: 416 · 423.17 · 431.68 · 436.57
UNH is in a clear short-term downtrend after peaking in the $430s in early-to-mid July 2026, with MACD collapsing from ~+22 in mid-May to just +0.82 on Aug-04 (histogram -2.97) and RSI slipping to 43.09. Price closed at 407.55, below the 50 SMA (410.64) and below the lower Bollinger Band (409.78)—a stretched oversold extreme. The 200-day SMA at 342.06 remains far below price and confirms the primary uptrend is intact. Tactical verdict: HOLD with downside risk; only re-enter on confirmed bounce off the 50-day SMA or bullish MACD crossover.
Market Cap
$370.1B
P/E (TTM)
30.67
Forward P/E
18.17
PEG Ratio
1.28
P/B
3.53
EPS (TTM)
$13.29
Forward EPS
$22.44
Dividend Yield
2.24%
Beta
0.63
52-Week High
$461.62
52-Week Low
$239.50
50-Day MA
$410.16
200-Day MA
$344.69
TTM Revenue
$450.1B
TTM Net Income
$14.1B
TTM EBITDA
$24.3B
TTM Operating CF
~$28.6B
TTM Free Cash Flow
$22.8B
TTM CapEx
~$3.5B
TTM Dividends Paid
~$8.0B
Profit Margin
3.14%
Operating Margin
7.13%
Gross Margin
19.5%
ROE
14.15%
ROA
4.38%
Q1 2026 Revenue
$111.7B
Q1 2026 Gross Profit
$25.4B
Q1 2026 Operating Income
$8.99B
Q1 2026 Net Income
$6.28B
Q1 2026 Diluted EPS
$6.90
Q4 2025 Revenue
$113.2B
Q4 2025 Gross Profit
$18.5B
Q4 2025 Operating Income
$0.38B
Q4 2025 Net Income
$0.01B
Q4 2025 Diluted EPS
$0.01
Q3 2025 Net Income
$2.35B
Q3 2025 Diluted EPS
$2.59
Q2 2025 Net Income
$3.41B
Q2 2025 Diluted EPS
$3.74
Q1 2025 Net Income
$6.29B
Q1 2025 Diluted EPS
$6.85
Q1 2026 Total Assets
$312.6B
Q1 2026 Stockholders' Equity
$97.9B
Q1 2026 Total Debt
$77.9B
Q1 2026 Net Debt
$49.9B
Q1 2026 Cash & Equivalents
$28.0B
Q1 2026 Goodwill
$110.5B
Q1 2026 Current Ratio
0.78
Q1 2026 Debt/Equity
69.2
Q1 2026 Operating CF
$8.91B
Q1 2026 CapEx
-$0.76B
Q1 2026 Free Cash Flow
$8.15B
Q1 2026 Dividends
-$2.01B
Q4 2025 Operating CF
$1.11B
Q4 2025 CapEx
-$0.95B
Q4 2025 Free Cash Flow
$0.16B
Effective Tax Rate
~18.6%
Q1 2026 Operating Margin
8.0%
Strengths
Concerns
UnitedHealth Group is the largest healthcare insurance and services conglomerate in the United States, operating through UnitedHealthcare (insurance serving ~50M+ individuals) and Optum (health services platform spanning pharmacy, care delivery, and analytics). The company is in a transitional recovery phase following a major Q4 2025 disruption that collapsed net income to just $10M ($0.01 EPS) due to likely Change Healthcare cyberattack remediation and elevated medical loss ratio costs. Q1 2026 demonstrated a strong rebound with EPS of $6.90 matching year-ago levels. The market is pricing in substantial earnings recovery with Forward P/E of 18.17x versus TTM P/E of 30.67x, implying EPS normalization to $22.44 (~69% recovery). The balance sheet is stable with $312.6B in assets, $97.9B equity, and debt reduced from $81.3B to $77.9B YoY. Cash generation remains best-in-class with $22.8B TTM free cash flow supporting dividends ($8B annualized) and future buyback resumption. The stock trades near 52-week highs above both moving averages with defensive beta of 0.63.